Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Covington
Chinese Patent Office
Baxter
Harvard Business School
Argus Health

Generated: April 20, 2019

DrugPatentWatch Database Preview

Sanofi Company Profile

« Back to Dashboard

Summary for Sanofi

Drugs and US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021629-002 Dec 20, 2005 DISCN Yes No 7,696,162 ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us ALLEGRA fexofenadine hydrochloride SUSPENSION;ORAL 021963-001 Oct 16, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us TORNALATE bitolterol mesylate AEROSOL, METERED;INHALATION 018770-001 Dec 28, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No 9,604,008 ➤ Sign Up Y ➤ Sign Up
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes 9,526,844 ➤ Sign Up Y ➤ Sign Up
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes 8,556,864 ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us ARALEN HYDROCHLORIDE chloroquine hydrochloride INJECTABLE;INJECTION 006002-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us TAXOTERE docetaxel INJECTABLE;INJECTION 020449-004 Aug 2, 2010 5,714,512*PED ➤ Sign Up
Sanofi Aventis Us ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 5,578,610*PED ➤ Sign Up
Sanofi Aventis Us ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-008 Jan 24, 2011 7,135,571*PED ➤ Sign Up
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-002 Jan 24, 2011 6,187,791 ➤ Sign Up
Sanofi Aventis Us ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-007 Jan 24, 2011 6,037,353*PED ➤ Sign Up
Sanofi Aventis Us ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-007 Jan 24, 2011 6,399,632*PED ➤ Sign Up
Sanofi Aventis Us ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 5,932,247*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Powder for Oral Suspension 0.8 g/packet and 2.4 g/packet ➤ Subscribe 2009-12-30
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 2004-05-25
➤ Subscribe Capsules 0.4 mg ➤ Subscribe 2004-12-20
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-03-04
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 2009-06-30
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2007-02-09
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 2011-03-23
➤ Subscribe Oral Solution 0.5 mg/mL ➤ Subscribe 2009-01-14
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2006-02-24
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
➤ Subscribe Tablets 7 mg and 14 mg ➤ Subscribe 2016-09-12
➤ Subscribe Tablets 800 mg ➤ Subscribe 2008-12-04
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 2006-06-06
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 2010-01-25
➤ Subscribe Tablets 400 mg ➤ Subscribe 2013-07-01
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 2014-05-30
➤ Subscribe Tablets 150 mg ➤ Subscribe 2007-10-30
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2007-02-09
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 2007-07-16
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 2006-12-07
➤ Subscribe Tablets 5 mg ➤ Subscribe 2007-12-17
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 2006-01-19
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 2004-11-10
Premature patent expirations for SANOFI

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Supplementary Protection Certificates for Sanofi Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203431 1590018-6 Sweden ➤ Sign Up PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
2498802 2017/022 Ireland ➤ Sign Up PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111
0281459 35/1998 Austria ➤ Sign Up PRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
1196444 2013/015 Ireland ➤ Sign Up PRODUCT NAME: LIXISENATIDE; NAT REGISTRATION NO/DATE: EU/1/12/811/001 20130201; FIRST REGISTRATION NO/DATE: EU/1/12/811/002 01/02/2013 IRELAND EU/1/12/811/003 01/02/2013 IRELAND EU/1/12/811/004 01/02/2013 IRELAND EU/1/12/811/005 20130201
1007030 SPC/GB10/029 United Kingdom ➤ Sign Up PRODUCT NAME: DRONEDARONE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/09/591/001 20091126; UK EU/1/09/591/002 20091126; UK EU/1/09/591/003 20091126; UK EU/1/09/591/004 20091126
2107069 1390036-0 Sweden ➤ Sign Up PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
1744764 300960 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
Cantor Fitzgerald
Johnson and Johnson
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.